Dose-Finding Study of E7070 in Combination With Irinotecan

NCT00060567 | Completed Phase 1

• 1 other identifier: E7070-A001-106
• Study Type: interventional
• Target: 88
• Locations: 1 country
• Sites: 1

Brief Summary

E7070 and irinotecan will be administered to patients with GI tract, pancreatic or lung tumors on Days 1 and 8 of a 21-day cycle, or Days 1 and 15 of a 28-day cycle according to one of two E7070 dose escalation schemes.

Conditions

Cancer

Keywords

E7070; Irinotecan; hydrochloride; gastrointestinal; cancer

Outcome Measures

Primary Outcomes (1)

• To determine the Maximum tolerated dose of E7070 in combination with irinotecan in patients with GI tract, pancreatic or lung tumors.

  1st arm: D1, D8, Q3WK; 2nd arm: D1, D8, Q3WK; 3rd arm: D1, D15, Q4WK

Secondary Outcomes (1)

• Safety, E7070 activity and Pharmacokinetics

  1st arm: D1, D8, Q3WK; 2nd arm: D1, D8, Q3WK; 3rd arm: D1, D15, Q4WK

Study Arms (3)

1

OTHER

Active combination of E7070 and irinotecan.

Drug: E7070 + irinotecan combination

2

OTHER

Active combination of E7070 and irinotecan.

Drug: Irinotecan + E7070 combination

3

OTHER

Active combination of E7070 and irinotecan.

Drug: Irinotecan + E7070 combination

Interventions

E7070 + irinotecan combination DRUG

Escalating doses starting from 125 mg/m2 irinotecan plus 250 mg/m2 E7070 combination.

1

Irinotecan + E7070 combination DRUG

Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.

2

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must have a histologically or cytologically confirmed refractory small cell lung carcinoma or relapsed pancreatic cancer.
• Patients should not have received more than two previous regimens of chemotherapy (prior epidermal growth factor directed therapy antiangiogenic therapy, or capecitabine do not constitute a previous regimen),
• Patients must be aged greater than or equal to 18 years,
• Patients must be ambulatory and have a Karnofsky performance status greater than or equal to 70%,
• Patients must have a life expectancy of greater than or equal to 3 months,
• Patients must meet the following screening hematologic values:
• Hemoglobin greater than or equal to 10g /dL
• Absolute Neutrophil Count greater than or equal to 1.5 x 10\^9/L
• Platelets greater than or equal to 100 x 109/L,
• Patients must meet the following screening values for liver function:
• Serum bilirubin less than or equal to 1.5 x upper limits of normal (ULN)
• ALAT and ASAT less than or equal to 2.5 x ULN (unless related to liver metastases, in which case less than or equal to 5 x ULN),
• Patients must have serum creatinine less than or equal to 1.5 x ULN,
• Patients must be willing and able to comply with the study protocol for the duration of the study, and
• Patients must give written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.

You may not qualify if:

• Patients who have received chemotherapy or radiation therapy (except palliative) or who have had major surgery within four weeks of treatment start,
• Patients who have received chemotherapy without recovering from chemotherapy related toxicity (defined as grade 1 or less) at study entry,
• Patients who have received palliative radiation therapy without recovering from radiation associated toxicity at study entry,
• Patients with a history of hypersensitivity to irinotecan,
• Patients who experienced greater than or equal to Grade 3 toxicity during previous therapy with irinotecan,
• Women who are pregnant or breastfeeding. Women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test. Women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator (postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential),
• Fertile men who are not willing to use contraception or fertile men with a female partner who is not willing to use contraception,
• Any history of uncontrolled seizures; CNS disorders; or psychological, familial, sociological or geographical conditions, judged by the Investigator to be clinically significant, and/or potentially capable of precluding informed consent or adversely affecting compliance with the study protocol and follow-up schedule,
• Patients must not have untreated brain metastases (Patients who have been treated for CNS metastases must be asymptomatic and radiologically stable for 4 weeks prior to entry),
• Patients with a history of conjugated hyperbilirubinemia,
• Patients with clinically significant cardiac or cardiovascular impairment,
• Patients with severe uncontrolled intercurrent infections,
• Patients with organ allografts,
• Patients who are receiving investigational drug treatment, immunotherapy, or biologic therapy. Treatment must have been completed four weeks prior to entry into the study and patients must have recovered from any associated toxicity.
• Patients with a history of hypersensitivity to sulfonamides,

Sponsors & Collaborators

• Eisai Inc.: lead

Study Sites (1)

Unknown Facility

Boston, Massachusetts, United States

Location

MeSH Terms

Conditions

Neoplasms

Interventions

N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide; Irinotecan

Intervention Hierarchy (Ancestors)

Camptothecin; Alkaloids; Heterocyclic Compounds

Study Officials

• Eisai Medical Services

  Eisai Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 7, 2003
• First Posted: May 9, 2003
• Study Start: March 1, 2003
• Primary Completion: March 1, 2013
• Study Completion: March 1, 2013
• Last Updated: June 18, 2023

Record last verified: 2013-06

Locations

US (1)